Bhere D, Khajuria RK, Hendriks WT, Bandyopadhyay A, Bagci-Onder T, Shah K
Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies. Stem Cells. 2018 06; 36(6):932-942.
Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies.
Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X, Weissleder R
In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther. 2003 Sep 01; 14(13):1247-54.
In vivo tracking of neural progenitor cell migration to glioblastomas.
JPMA. The Journal of the Pakistan Medical Association
Peri-operative management of a patient with uncontrolled Polycythemia Vera for above knee amputation. J Pak Med Assoc. 2004 Jan; 54(1):34-6.
Peri-operative management of a patient with uncontrolled Polycythemia Vera for above knee amputation.
Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 2007 Oct 01; 67(19):8994-9000.
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas.
Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO
Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res. 2004 May 01; 64(9):3236-42.
Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy.
Heidari P, Kunawudhi A, Martinez-Quintanilla J, Szretter A, Shah K, Mahmood U
Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. Theranostics. 2018; 8(12):3380-3391.
Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions.
Nesterenko I, Wanningen S, Bagci-Onder T, Anderegg M, Shah K
Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One. 2012; 7(11):e49219.
Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.
Tung CH, Zeng Q, Shah K, Kim DE, Schellingerhout D, Weissleder R
In vivo imaging of beta-galactosidase activity using far red fluorescent switch. Cancer Res. 2004 Mar 01; 64(5):1579-83.
In vivo imaging of beta-galactosidase activity using far red fluorescent switch.
Neural precursor cells and their role in neuro-oncology. Dev Neurosci. 2004 Mar-Aug; 26(2-4):118-30.
Neural precursor cells and their role in neuro-oncology.
Kumar AT, Chung E, Raymond SB, van de Water JA, Shah K, Fukumura D, Jain RK, Bacskai BJ, Boas DA
Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Opt Lett. 2009 Jul 01; 34(13):2066-8.
Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast.
Methods in molecular biology (Clifton, N.J.)
Imaging fate of stem cells at a cellular resolution in the brains of mice. Methods Mol Biol. 2011; 680:91-101.
Imaging fate of stem cells at a cellular resolution in the brains of mice.
Reinshagen C, Bhere D, Choi SH, Hutten S, Nesterenko I, Wakimoto H, Le Roux E, Rizvi A, Du W, Minicucci C, Shah K
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. Sci Transl Med. 2018 07 11; 10(449).
CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors.
Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia. 2007 May; 9(5):435-42.
Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL.
Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K
Proceedings of the National Academy of Sciences of the United States of America
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009 Mar 24; 106(12):4822-7.
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.
van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R, Shah K
Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene. 2010 Jun 03; 29(22):3185-95.
Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors.
Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther. 2008 Nov; 7(11):3575-85.
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
Guo Y, Yuan H, Cho H, Kuruppu D, Jokivarsi K, Agarwal A, Shah K, Josephson L
High efficiency diffusion molecular retention tumor targeting. PLoS One. 2013; 8(3):e58290.
High efficiency diffusion molecular retention tumor targeting.
Martinez-Quintanilla J, Bhere D, Heidari P, He D, Mahmood U, Shah K
Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells. 2013 08; 31(8):1706-14.
Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors.
Passaro C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H
Clinical cancer research : an official journal of the American Association for Cancer Research
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res. 2019 01 01; 25(1):290-299.
Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.
Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB, Sarkar D
Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res. 2010 Apr 15; 70(8):3249-58.
Molecular mechanism of chemoresistance by astrocyte elevated gene-1.
Kuruppu D, Bhere D, Farrar CT, Shah K, Brownell AL, Tanabe KK
A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. Cancer Gene Ther. 2019 05; 26(5-6):145-156.
A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging.
Shah K, Tang Y, Breakefield X, Weissleder R
Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene. 2003 Oct 09; 22(44):6865-72.
Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.
Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, Ramakrishnan V, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB, Dent P
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther. 2008 Jun; 7(6):917-33.
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors.
In vivo imaging of the dynamics of different variants of EGFR in glioblastomas. Methods Mol Biol. 2011; 680:153-64.
In vivo imaging of the dynamics of different variants of EGFR in glioblastomas.
Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H
Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139.
Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.
Engineered and Encapsulated Stem Cells for Resected Brain Tumors
Harvey W. Cushing and Daniel E. Ponton Professor of Neurosurgery
A. Werk Cook Professor of Radiation Oncology (Tumor Biology)
Engineered stem cells targeting multiple cell surface receptors in tumors. Stem Cells. 2020 01; 38(1):34-44.
Engineered stem cells targeting multiple cell surface receptors in tumors.
Bhere D, Arghiani N, Lechtich ER, Yao Y, Alsaab S, Bei F, Matin MM, Shah K
Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Sci Rep. 2020 02 04; 10(1):1779.
Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy.
Mineo M, Lyons SM, Zdioruk M, von Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, Kharel P, Giantini Larsen A, Fan WY, Auduong S, Grauwet K, Passaro C, Khalsa JK, Shah K, Reardon DA, Ligon KL, Beroukhim R, Nakashima H, Ivanov P, Anderson PJ, Lawler SE, Chiocca EA
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8.
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends Pharmacol Sci. 2020 09; 41(9):653-664.
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential.
TRAIL of Hope Meeting Resistance in Cancer. Trends Cancer. 2020 12; 6(12):989-1001.
TRAIL of Hope Meeting Resistance in Cancer.
Khalsa JK, Cheng N, Keegan J, Chaudry A, Driver J, Bi WL, Lederer J, Shah K
Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nat Commun. 2020 08 06; 11(1):3912.
Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Front Oncol. 2020; 10:1182.
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics.
Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R, Alturki M, Fallatah M, Almalik A, Alhasan AH, Shah K, Karp JM
Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020 07; 6(30):eaba6884.
Shattering barriers toward clinically meaningful MSC therapies.
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, Vangos NE, Yeoh ZC, Geffken EA, Seo HS, Liu ZX, Heffron GJ, Shah K, Dhe-Paganon S, Abdi R
Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell. 2020 11 25; 183(5):1219-1233.e18.
Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy.
Akter F, Simon B, de Boer NL, Redjal N, Wakimoto H, Shah K
Biochimica et biophysica acta. Reviews on cancer
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochim Biophys Acta Rev Cancer. 2021 01; 1875(1):188458.
Pre-clinical tumor models of primary brain tumors: Challenges and opportunities.
Kiyokawa J, Kawamura Y, Ghouse SM, Acar S, Barçin E, Martínez-Quintanilla J, Martuza RL, Alemany R, Rabkin SD, Shah K, Wakimoto H
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021 02 01; 27(3):889-902.
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Jiang L, Jung S, Zhao J, Kasinath V, Ichimura T, Joseph J, Fiorina P, Liss AS, Shah K, Annabi N, Joshi N, Akama TO, Bromberg JS, Kobayashi M, Uchimura K, Abdi R
Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery. Nano Today. 2021 Feb; 36.
Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery.
Song N, Wakimoto H, Rossignoli F, Bhere D, Ciccocioppo R, Chen KS, Khalsa JK, Mastrolia I, Samarelli AV, Dominici M, Shah K
Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells. 2021 06; 39(6):707-722.
Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
Kitamura Y, Kanaya N, Moleirinho S, Du W, Reinshagen C, Attia N, Bronisz A, Revai Lechtich E, Sasaki H, Mora JL, Brastianos PK, Falcone JL, Hofer AM, Franco A, Shah K
Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Sci Adv. 2021 03; 7(10).
Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.
Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies. Cells. 2021 02 25; 10(3).
Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies.
López Vázquez M, Du W, Kanaya N, Kitamura Y, Shah K
Next-generation immunotherapies for brain metastatic cancers. Trends Cancer. 2021 09; 7(9):809-822.
Next-generation immunotherapies for brain metastatic cancers.
Cingöz A, Ozyerli-Goknar E, Morova T, Seker-Polat F, Esai Selvan M, Gümüs ZH, Bhere D, Shah K, Solaroglu I, Bagci-Onder T
Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene. 2021 May; 40(18):3201-3216.
Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
Yang Q, Luo C, Zhang X, Liu Y, Wang Z, Cacciamani P, Shi J, Cui Y, Wang C, Sinha B, Peng B, Tong G, Das G, Shah E, Gao Y, Li W, Tu Y, Qian D, Shah K, Akbar M, Zhou S, Song BJ, Wang X
American journal of translational research
Tartary buckwheat extract alleviates alcohol-induced acute and chronic liver injuries through the inhibition of oxidative stress and mitochondrial cell death pathway. Am J Transl Res. 2020; 12(1):70-89.
Tartary buckwheat extract alleviates alcohol-induced acute and chronic liver injuries through the inhibition of oxidative stress and mitochondrial cell death pathway.
Karakas N, Stuckey D, Revai-Lechtich E, Shah K
International journal of molecular medicine
IL13Ra2- and EGFR-targeted pseudomonas exotoxin potentiates the TRAIL-mediated death of GBM cells. Int J Mol Med. 2021 Jul; 48(1).
IL13Ra2- and EGFR-targeted pseudomonas exotoxin potentiates the TRAIL-mediated death of GBM cells.
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy? Front Oncol. 2021; 11:678562.
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K, Alomary MN, Zaidan N
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells. 2021 06 18; 10(6).
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer.
Tawfik EA, Aldrak NA, Albrahim SH, Alzahrani DA, Alfassam HA, Alkoblan SM, Almalik AM, Chen KS, Abou-Khalil R, Shah K, Zaidan NM
Immunotherapy in hematological malignancies: recent advances and open questions. Immunotherapy. 2021 10; 13(14):1215-1229.
Immunotherapy in hematological malignancies: recent advances and open questions.
Martinez-Quintanilla J, Seah I, Chua M, Shah K
Oncolytic viruses: overcoming translational challenges. J Clin Invest. 2019 03 04; 129(4):1407-1418.
Oncolytic viruses: overcoming translational challenges.
Modulating microRNAs in cancer: next-generation therapies. Cancer Biol Med. 2021 Dec 01; 19(3).
Modulating microRNAs in cancer: next-generation therapies.
NK cells in the brain: implications for brain tumor development and therapy. Trends Mol Med. 2022 03; 28(3):194-209.
NK cells in the brain: implications for brain tumor development and therapy.
Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine. 2022 Mar; 77:103908.
Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS.
The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review. JAMA Oncol. 2022 07 01; 8(7):1059-1067.
The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm: A Review.
Bhere D, Choi SH, van de Donk P, Hope D, Gortzak K, Kunnummal A, Khalsa J, Revai Lechtich E, Reinshagen C, Leon V, Nissar N, Bi WL, Feng C, Li H, Zhang YS, Liang SH, Vasdev N, Essayed W, Quevedo PV, Golby A, Banouni N, Palagina A, Abdi R, Fury B, Smirnakis S, Lowe A, Reeve B, Hiller A, Chiocca EA, Prestwich G, Wakimoto H, Bauer G, Shah K
Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nat Commun. 2022 05 19; 13(1):2810.
Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells.
Karakas N, Bay S, Türkel N, Öztunç N, Öncül M, Bilgen H, Shah K, Sahin F, Öztürk G
Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity. PLoS One. 2020; 15(5):e0228510.
Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity.
Lee YH, Pang SW, Revai Lechtich E, Shah K, Simon SE, Ponnusamy S, Narayanan R, Poh CL, Tan KO
Journal of cancer research and clinical oncology
Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1. J Cancer Res Clin Oncol. 2020 Jul; 146(7):1751-1764.
Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1.
Ishii Y, Kolluri KK, Pennycuick A, Zhang X, Nigro E, Alrifai D, Borg E, Falzon M, Shah K, Kumar N, Janes SM
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma. J Biol Chem. 2021 11; 297(5):101223.
BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.
Karakas N, Üçüncüoglu S, Uludag D, Karaoglan BS, Shah K, Öztürk G
Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells. 2022 01 29; 11(3).
Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives.
Vaughan HJ, Zamboni CG, Radant NP, Bhardwaj P, Revai Lechtich E, Hassan LF, Shah K, Green JJ
Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Mol Ther Oncolytics. 2021 Jun 25; 21:377-388.
Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer.
Chen KS, Reinshagen C, Van Schaik TA, Rossignoli F, Borges P, Mendonca NC, Abdi R, Simon B, Reardon DA, Wakimoto H, Shah K
Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity. Sci Transl Med. 2023 01 04; 15(677):eabo4778.
Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity.
Kuruppu D, Bhere D, Farrar CT, Shah K, Brownell AL, Mahmood U, Tanabe KK
Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases. Cancer Gene Ther. 2023 06; 30(6):833-844.
Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases.
Alkayyal AA, Ajina R, Cacciabue M, Alkayyal AA, Saeedi NH, Hussain Alshehry T, Kaboha F, Alotaibi MA, Zaidan N, Shah K, Alroqi F, Bakur Mahmoud A
SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus. Front Immunol. 2023; 14:1082191.
SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus.
Correction to: Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases. Cancer Gene Ther. 2023 Jun; 30(6):927.
Correction to: Oncolytic HSV1 targets different growth phases of breast cancer leptomeningeal metastases.
van Schaik TA, Moreno-Lama L, Aligholipour Farzani T, Wang M, Chen KS, Li W, Cai L, Zhang YS, Shah K
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors. Biomed Pharmacother. 2023 Jun; 162:114665.
Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors.
Kanaya N, Kitamura Y, Lopez Vazquez M, Franco A, Chen KS, van Schaik TA, Farzani TA, Borges P, Ichinose T, Seddiq W, Kuroda S, Boland G, Jahan N, Fisher D, Wakimoto H, Shah K
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas. Sci Transl Med. 2023 05 31; 15(698):eade8732.
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas.
Moleirinho S, Kitamura Y, Borges PSGN, Auduong S, Kilic S, Deng D, Kanaya N, Kozono D, Zhou J, Gray JJ, Revai-Lechtich E, Zhu Y, Shah K
Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer. Stem Cells Transl Med. 2023 07 14; 12(7):444-458.
Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer.
Developing and characterizing a two-layered safety switch for cell therapies. Cancer Biol Ther. 2023 12 31; 24(1):2232146.
Developing and characterizing a two-layered safety switch for cell therapies.
Melloni A, Liu L, Kashinath V, Abdi R, Shah K
Meningeal lymphatics and their role in CNS disorder treatment: moving past misconceptions. Front Neurosci. 2023; 17:1184049.
Meningeal lymphatics and their role in CNS disorder treatment: moving past misconceptions.
Taming CAR T cell therapy toxicity. Nat Mater. 2023 12; 22(12):1444-1445.
Targeting metastatic tumors with engineered cellular therapies
Liu L, van Schaik TA, Chen KS, Rossignoli F, Borges P, Vrbanac V, Wakimoto H, Shah K
Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice. Front Immunol. 2023; 14:1324618.
Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice.
Valdes PA, Yu CJ, Aronson J, Ghosh D, Zhao Y, An B, Bernstock JD, Bhere D, Felicella MM, Viapiano MS, Shah K, Chiocca EA, Boyden ES
Improved immunostaining of nanostructures and cells in human brain specimens through expansion-mediated protein decrowding. Sci Transl Med. 2024 01 31; 16(732):eabo0049.
Improved immunostaining of nanostructures and cells in human brain specimens through expansion-mediated protein decrowding.
Choi SH, Tamura K, Khajuria RK, Bhere D, Nesterenko I, Lawler J, Shah K
Molecular therapy : the journal of the American Society of Gene Therapy
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas. Mol Ther. 2024 Jun 05; 32(6):2030.
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas.
Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas. Mol Ther. 2024 May 01; 32(5):1595.
Vogiatzi I, Lama LM, Lehmann A, Rossignoli F, Gettemans J, Shah K
Allogeneic stem cells engineered to release interferon ß and scFv-PD1 target glioblastoma and alter the tumor microenvironment. Cytotherapy. 2024 Oct; 26(10):1217-1226.
Allogeneic stem cells engineered to release interferon ß and scFv-PD1 target glioblastoma and alter the tumor microenvironment.
Author Correction: Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Sci Rep. 2024 Jul 03; 14(1):15303.
Author Correction: Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy.
Correction: Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene. 2024 Aug; 43(35):2677.
Correction: Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.
Corrigendum to "Tumor Therapy Mediated by Lentiviral Expression of shBcl-2 and S-TRAIL" [Neoplasia. Vol. 9, No. 5, May 2007, pp. 435-442]. Neoplasia. 2024 Oct; 56:101027.
Corrigendum to "Tumor Therapy Mediated by Lentiviral Expression of shBcl-2 and S-TRAIL" [Neoplasia. Vol. 9, No. 5, May 2007, pp. 435-442].
Cingöz A, Ozyerli-Goknar E, Morova T, Seker-Polat F, Selvan ME, Gümüs ZH, Bhere D, Shah K, Solaroglu I, Bagci-Onder T
Editorial Expression of Concern: Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization. Oncogene. 2024 08; 43(34):2612.
Editorial Expression of Concern: Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.
Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P
Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma. Mol Ther. 2024 12 04; 32(12):4524.
Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma.
Corrigendum: Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice. Front Immunol. 2024; 15:1466387.
Corrigendum: Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice.
Role of threonines in the Arabidopsis thaliana somatic embryogenesis receptor kinase 1 activation loop in phosphorylation. J Biol Chem. 2001 Nov 02; 276(44):41263-9.
Role of threonines in the Arabidopsis thaliana somatic embryogenesis receptor kinase 1 activation loop in phosphorylation.
A zwitterionic twist. Nat Rev Chem. 2024 Oct; 8(10):721.
Chen KS, Manoury-Battais S, Kanaya N, Vogiatzi I, Borges P, Kruize SJ, Chen YC, Lin LY, Rossignoli F, Mendonca NC, Shah K
An inducible RIPK3-driven necroptotic system enhances cancer cell-based immunotherapy and ensures safety. J Clin Invest. 2024 Nov 19; 135(2).
An inducible RIPK3-driven necroptotic system enhances cancer cell-based immunotherapy and ensures safety.
Hajji N, Garcia-Revilla J, Soto MS, Perryman R, Symington J, Quarles CC, Healey DR, Guo Y, Orta-Vázquez ML, Mateos-Cordero S, Shah K, Bomalaski J, Anichini G, Tzakos AG, Crook T, O'Neill K, Scheck AC, Venero JL, Syed N
Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. J Clin Invest. 2022 03 15; 132(6).
Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors.
Correction: A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. Cancer Gene Ther. 2024 Dec; 31(12):1895.
Correction: A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging.
Cell surface receptor targeted therapies for brain tumors
TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 2013 Nov; 19(11):685-94.
TRAIL on trial: preclinical advances in cancer therapy.
Kanaya N, Seddiq W, Chen KS, Kajiwara Y, Moreno Lama L, Borges P, Kuroda S, Wakimoto H, Shah K
Journal of the National Cancer Institute
Engineered allogeneic stem cells orchestrate T lymphocyte-driven immunotherapy in immunosuppressive leptomeningeal brain metastasis. J Natl Cancer Inst. 2025 Jun 01; 117(6):1151-1165.
Engineered allogeneic stem cells orchestrate T lymphocyte-driven immunotherapy in immunosuppressive leptomeningeal brain metastasis.
van Schaik TA, Chen KS, Kanaya N, Moreno-Lama L, Freeman NW, Wang M, Li W, Zhang YS, Vrbanac V, Huang R, Wakimoto H, Reardon D, Shah K
Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation. Clin Cancer Res. 2025 Jul 01; 31(13):2793-2813.
Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation.
Bhere D, Choi SH, van de Donk P, Hope D, Gortzak K, Kunnummal A, Khalsa J, Lechtich ER, Reinshagen C, Leon V, Nissar N, Bi WL, Feng C, Li H, Zhang YS, Liang SH, Vasdev N, Essayed W, Quevedo PV, Golby A, Banouni N, Palagina A, Abdi R, Fury B, Smirnakis S, Lowe A, Reeve B, Hiller A, Chiocca EA, Prestwich G, Wakimoto H, Bauer G, Shah K
Retraction Note: Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nat Commun. 2025 Mar 21; 16(1):2803.
Retraction Note: Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells.
Encapsulated Cell Based Oncolytic Virus Therapy for Brain Tumors
Harmonizing the Gut Microbiome and Cellular Immunotherapies: The Next Leap in Cancer Treatment. Cells. 2025 05 14; 14(10).
Harmonizing the Gut Microbiome and Cellular Immunotherapies: The Next Leap in Cancer Treatment.
Liu C, Huang X, Chen KS, Xiong S, Yaremenko AV, Zhen X, You X, Rossignoli F, Tang Y, Koo S, Chen W, Kong N, Xie T, Shah K, Tao W
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles. Nat Nanotechnol. 2025 Oct; 20(10):1526-1538.
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles.
Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors. PLoS One. 2014; 9(4):e95490.
Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors.
Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, Shah K
Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014 Jun; 106(6):dju090.
Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.
Kuruppu D, Brownell AL, Shah K, Mahmood U, Tanabe KK
Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability. Cancer Res. 2014 Aug 01; 74(15):4111-21.
Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability.
Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biol Ther. 2014 Jun 01; 15(6):815-22.
Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.
Vogiatzi I, Lehmann A, Liu C, Moreno-Lama L, Kajiwara Y, Kanaya N, Zwaenepoel O, Farid AS, Lee UJ, Rossignoli F, Rashidian M, Wakimoto H, Gettemans J, Shah K
A nanobody-stem cell platform targeting innate and adaptive immune axis in the tumour microenvironment. EBioMedicine. 2026 Feb; 124:106122.
A nanobody-stem cell platform targeting innate and adaptive immune axis in the tumour microenvironment.
Emerging innovative treatments for leptomeningeal metastatic tumors. Trends Mol Med. 2025 Nov 18.
Emerging innovative treatments for leptomeningeal metastatic tumors.
Repurposing Tumor Cells: A Paradigm Shift in Cell-Based Therapies for Cancer. Clin Cancer Res. 2026 Feb 20.
Repurposing Tumor Cells: A Paradigm Shift in Cell-Based Therapies for Cancer.
Author Correction: Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nat Commun. 2025 Jun 12; 16(1):5307.
Author Correction: Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.
Beyond safety: suicide systems in cell-based cancer therapies. Trends Cancer. 2025 Oct; 11(10):966-978.
Beyond safety: suicide systems in cell-based cancer therapies.
Gronich N, Geva-Zatorsky N, Herren R, Kelly L, Cohen Z, Zhou H, Chen YC, Shah K, Robinson-Catala TA, Frisby G, Karnes JH, Shoda L
Pharmacomicrobiomics. Clin Pharmacol Ther. 2025 Dec; 118(6):1366-1377.
Kauer TM, Figueiredo JL, Hingtgen S, Shah K
Author Correction: Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci. 2026 Mar; 29(3):760.
Author Correction: Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas.
Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA
Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.
Brain tumor cells in circulation are enriched for mesenchymal gene expression.
Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer. 2014 10; 14(10):683-91.
Stem cell-based therapies for cancer treatment: separating hope from hype.
Stuckey DW, Hingtgen SD, Karakas N, Rich BE, Shah K
Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells. 2015 Feb; 33(2):589-600.
Engineering toxin-resistant therapeutic stem cells to treat brain tumors.
Response. J Natl Cancer Inst. 2015 Jan; 107(1):370.
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells. 2015 01; 33(1):101-10.
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
Martinez-Quintanilla J, He D, Wakimoto H, Alemany R, Shah K
Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther. 2015 Jan; 23(1):108-18.
Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.
Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Mol Ther. 2015 02; 23(2):235-43.
Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas.
Bagci-Onder T, Du W, Figueiredo JL, Martinez-Quintanilla J, Shah K
Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain. 2015 Jun; 138(Pt 6):1710-21.
Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells.
Stem Cell-Based Therapies for Cancer. Adv Cancer Res. 2015; 127:159-89.
Wehrenberg-Klee E, Redjal N, Leece A, Turker NS, Heidari P, Shah K, Mahmood U
American journal of nuclear medicine and molecular imaging
PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance. Am J Nucl Med Mol Imaging. 2015; 5(4):379-89.
PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance.
Multifunctional receptor-targeting antibodies for cancer therapy. Lancet Oncol. 2015 Nov; 16(15):e543-e554.
Multifunctional receptor-targeting antibodies for cancer therapy.
Stem cell-based therapies for tumors in the brain: are we there yet? Neuro Oncol. 2016 08; 18(8):1066-78.
Stem cell-based therapies for tumors in the brain: are we there yet?
Stem cell mediated targeting of tumor cells and associated vasculature in gliomas
Overcoming therapeutic resistance of gliomas
In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapy
Fate and efficacy of targeted therapies for metastatic tumors
In vivo imaging and therapeutic efficacy of NSC-secreted nanobodies
In vivo imaging of encapsulated stem cells in mouse models of tumor resection
Developing diagnostic and therapeutic stem cells for cancer therapy
Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics. Discov Med. 2016 09; 22(120):157-166.
Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics.
Srivastava J, Robertson CL, Rajasekaran D, Gredler R, Siddiq A, Emdad L, Mukhopadhyay ND, Ghosh S, Hylemon PB, Gil G, Shah K, Bhere D, Subler MA, Windle JJ, Fisher PB, Sarkar D
AEG-1 regulates retinoid X receptor and inhibits retinoid signaling. Cancer Res. 2014 Aug 15; 74(16):4364-77.
AEG-1 regulates retinoid X receptor and inhibits retinoid signaling.
NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics
Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx. 2005 Apr; 2(2):215-25.
Molecular optical imaging: applications leading to the development of present day therapeutics.
Kim DE, Schellingerhout D, Ishii K, Shah K, Weissleder R
Imaging of stem cell recruitment to ischemic infarcts in a murine model. Stroke. 2004 Apr; 35(4):952-7.
Imaging of stem cell recruitment to ischemic infarcts in a murine model.
Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol. 2008 Apr; 9(4):376-84.
Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare.
Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K
A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011 Jan 01; 71(1):154-63.
A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.
Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci. 2011 Dec 25; 15(2):197-204.
Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas.
Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, Weissleder R, Breakefield XO, Tung CH
A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia. 2004 Mar-Apr; 6(2):95-105.
A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe.
Retracted: Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther. 2010 06; 18(6):1130-1142.
Retracted: Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.
Shah K, Tung CH, Breakefield XO, Weissleder R
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol Ther. 2005 Jun; 11(6):926-31.
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis.
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int J Cancer. 2017 10 15; 141(8):1671-1681.
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Zhu Y, Bassoff N, Reinshagen C, Bhere D, Nowicki MO, Lawler SE, Roux J, Shah K
Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Sci Rep. 2017 06 01; 7(1):2602.
Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors.
Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, Motala Z, Durbin AD, Molodtsov A, Reeder S, Jin A, Sindiri S, Beleyea BC, Bhere D, Alexander MS, Shah K, Keller C, Linardic CM, Nielsen PG, Malkin D, Khan J, Langenau DM
The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep. 2017 06 13; 19(11):2304-2318.
The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma.
Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO, Weissleder R
In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res. 2004 Jan 01; 64(1):273-8.
In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas.
Current advances in molecular imaging of gene and cell therapy for cancer. Cancer Biol Ther. 2005 May; 4(5):518-23.
Current advances in molecular imaging of gene and cell therapy for cancer.
Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB, Sarkar D
Identification of genes conferring resistance to 5-fluorouracil. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12938-43.
Identification of genes conferring resistance to 5-fluorouracil.
Current opinion in molecular therapeutics
Stem-cell based therapies for brain tumors. Curr Opin Mol Ther. 2008 Aug; 10(4):334-42.
Stem-cell based therapies for brain tumors.
Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K
Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A. 2017 07 25; 114(30):E6157-E6165.
Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.
Choi SH, Stuckey DW, Pignatta S, Reinshagen C, Khalsa JK, Roozendaal N, Martinez-Quintanilla J, Tamura K, Keles E, Shah K
Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNß in Glioblastomas. Clin Cancer Res. 2017 Nov 15; 23(22):7047-7058.
Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNß in Glioblastomas.
Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R
The Journal of neuroscience : the official journal of the Society for Neuroscience
Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci. 2008 Apr 23; 28(17):4406-13.
Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model.
Emdad L, Sarkar D, Lee SG, Su ZZ, Yoo BK, Dash R, Yacoub A, Fuller CE, Shah K, Dent P, Bruce JN, Fisher PB
Astrocyte elevated gene-1: a novel target for human glioma therapy. Mol Cancer Ther. 2010 Jan; 9(1):79-88.
Astrocyte elevated gene-1: a novel target for human glioma therapy.
Hingtgen SD, Kasmieh R, van de Water J, Weissleder R, Shah K
A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. Stem Cells. 2010 Apr; 28(4):832-41.
A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy.
Lobbardi R, Pinder J, Martinez-Pastor B, Theodorou M, Blackburn JS, Abraham BJ, Namiki Y, Mansour M, Abdelfattah NS, Molodtsov A, Alexe G, Toiber D, de Waard M, Jain E, Boukhali M, Lion M, Bhere D, Shah K, Gutierrez A, Stegmaier K, Silverman LB, Sadreyev RI, Asara JM, Oettinger MA, Haas W, Look AT, Young RA, Mostoslavsky R, Dellaire G, Langenau DM
TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2017 11; 7(11):1336-1353.
TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia.
Arwert E, Hingtgen S, Figueiredo JL, Bergquist H, Mahmood U, Weissleder R, Shah K
Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res. 2007 Aug 01; 67(15):7335-42.
Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo.
Bhere D, Tamura K, Wakimoto H, Choi SH, Purow B, Debatisse J, Shah K
microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro Oncol. 2018 01 22; 20(2):215-224.
microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis.
van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen en Henegouwen PM, Shah K
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16642-7.
Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
HSV amplicon vectors for cancer therapy. Curr Gene Ther. 2006 Jun; 6(3):361-70.
HSV amplicon vectors for cancer therapy.
Premedication in surgical day care patients. J Pak Med Assoc. 2007 Jan; 57(1):37-8.
Premedication in surgical day care patients.
Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev. 2012 Jun 01; 64(8):739-48.
Mesenchymal stem cells engineered for cancer therapy.
Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO
Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol. 2005 Jan; 57(1):34-41.
Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.
Dent P, Yacoub A, Park M, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB
Searching for a cure: gene therapy for glioblastoma. Cancer Biol Ther. 2008 Sep; 7(9):1335-40.
Searching for a cure: gene therapy for glioblastoma.
Deliolanis NC, Kasmieh R, Wurdinger T, Tannous BA, Shah K, Ntziachristos V
Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications. J Biomed Opt. 2008 Jul-Aug; 13(4):044008.
Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications.
Encapsulated stem cells for cancer therapy. Biomatter. 2013 Jan-Mar; 3(1).
Encapsulated stem cells for cancer therapy.
Srivastava J, Siddiq A, Emdad L, Santhekadur PK, Chen D, Gredler R, Shen XN, Robertson CL, Dumur CI, Hylemon PB, Mukhopadhyay ND, Bhere D, Shah K, Ahmad R, Giashuddin S, Stafflinger J, Subler MA, Windle JJ, Fisher PB, Sarkar D
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology. 2012 Nov; 56(5):1782-91.
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
Hingtgen S, Kasmieh R, Elbayly E, Nesterenko I, Figueiredo JL, Dash R, Sarkar D, Hall D, Kozakov D, Vajda S, Fisher PB, Shah K
A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy. PLoS One. 2012; 7(7):e40234.
A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy.
Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K
Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013 Jan; 21(1):68-77.
Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.
Hingtgen S, Figueiredo JL, Farrar C, Duebgen M, Martinez-Quintanilla J, Bhere D, Shah K
Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. J Neurooncol. 2013 Jan; 111(2):153-61.
Real-time multi-modality imaging of glioblastoma tumor resection and recurrence.
Imaging neural stem cell fate in mouse model of glioma. Curr Protoc Stem Cell Biol. 2009 Mar; Chapter 5:Unit 5A.1.
Imaging neural stem cell fate in mouse model of glioma.
Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81.
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.